• Incremental Development,
    Exponential Value

  • Addressing a $15B+
    fast-growing market

  • Pioneering Solutions,
    Improving Women's Health

5th December 2018

Navad receives approval for it's Phase II trial from the Ethics Committee in Germany

13th December 2018

Navad receives approval for it's Phase II trial from BfArM

We are committed to improving women's health through innovative therapies that address large unmet needs.